PNR vs TNXP · P/E 18, rev $4.18B vs rev $20.4M
Pentair PLC (PNR) versus Tonix Pharmaceuticals Holding Corp (TNXP) — a side-by-side from cached financials, not a winner call.
Pentair PLC (PNR) is a specialty industrial machinery company listed on NYSE.
Tonix Pharmaceuticals Holding Corp (TNXP) is a biotechnology company listed on NASDAQ.
Latest reported PNR revenue for 2025-12-31 was $4.18B. Net income was $653.8M. Revenue was up 2.3% from 2024-12-31 to 2025-12-31. PNR currently screens at market cap $11.86B and trailing P/E 18.4.
Latest reported TNXP revenue for 2026-06-30 was $20.4M. Net income was -$80.7M. TNXP currently screens at market cap $194.5M.
PNR currently screens at market cap $11.86B and trailing P/E 18.4. TNXP currently screens at market cap $194.5M.
Not investment advice. Open the PNR and TNXP stock pages for the full models.
Not investment advice.